Balance between Innovation and Health Public Expenditure. The Particular Case of Biosimilars
Biosimilar medicines have been commercialized in the European regulatory territory for thirteen years. Its commercialization has not been exempted from multiple criticisms, especially the confusions about its erroneous equivalence with generic medicines and the doubts generated regarding its possibi...
| Autores Principales: | , |
|---|---|
| Formato: | Artículo (Article) |
| Lenguaje: | Español (Spanish) |
| Publicado: |
Departamento de Derecho Constitucional
2020
|
| Acceso en línea: | https://revistas.uexternado.edu.co/index.php/derest/article/view/6963 |